These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28811858)

  • 21. Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.
    Ito D; Ikuma-Suwa E; Inoue K; Kaneko K; Yanagisawa M; Inukai K; Noda M; Shimada A
    J Clin Med Res; 2017 Feb; 9(2):154-162. PubMed ID: 28090231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials.
    Kashiwagi A; Yoshida S; Kawamuki K; Nakamura I; Kazuta K; Ueyama E; Takahashi H; Akiyama N; Kondo Y; Ogihara T
    Diabetol Int; 2017 Mar; 8(1):76-86. PubMed ID: 30603310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study.
    Ito D; Inoue K; Sumita T; Hamaguchi K; Kaneko K; Yanagisawa M; Inukai K; Inoue I; Noda M; Shimada A
    J Clin Med Res; 2018 Sep; 10(9):679-687. PubMed ID: 30116437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study.
    Zang L; Han Y; Chen L; Hu D; Jin H; Yang N; Shi X; Liang L; Liu M; Fan H; Li Q; Mu Y
    Diabetes Ther; 2019 Aug; 10(4):1391-1405. PubMed ID: 31222594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.
    Yokote K; Terauchi Y; Nakamura I; Sugamori H
    Expert Opin Pharmacother; 2016 Oct; 17(15):1995-2003. PubMed ID: 27477242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
    Ohta A; Kato H; Ishii S; Sasaki Y; Nakamura Y; Nakagawa T; Nagai Y; Tanaka Y
    Expert Opin Pharmacother; 2017 Oct; 18(14):1433-1438. PubMed ID: 28770629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin.
    Al Omari M; Khader Y; Dauod AS; Beni Yonis OA; Khassawneh AH
    J Drug Assess; 2016; 5(1):29-33. PubMed ID: 27994943
    [No Abstract]   [Full Text] [Related]  

  • 28. Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy.
    Ishihara H; Yamaguchi S; Sugitani T; Kosakai Y
    Clin Drug Investig; 2019 Dec; 39(12):1213-1221. PubMed ID: 31552641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
    Gupta A
    Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study.
    El Ebrashy I; El Kafrawy N; Raouf R; Yousry D
    Diabetes Res Clin Pract; 2020 Apr; 162():108042. PubMed ID: 32006641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA
    Kim SR; Lee YH; Kang ES; Cha BS; Lee BW
    Diabetes Ther; 2017 Jun; 8(3):601-609. PubMed ID: 28332143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
    Tobe K; Maegawa H; Nakamura I; Uno S
    Diabetol Int; 2021 Apr; 12(2):181-196. PubMed ID: 33786273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.
    Yamamoto C; Miyoshi H; Ono K; Sugawara H; Kameda R; Ichiyama M; Yamamoto K; Nomoto H; Nakamura A; Atsumi T
    Endocr J; 2016 Jun; 63(6):589-96. PubMed ID: 27052123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.
    Ohkura T
    World J Diabetes; 2015 Feb; 6(1):136-44. PubMed ID: 25685284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Diabetes Ther; 2021 May; 12(5):1359-1378. PubMed ID: 33730336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study.
    Ueno H; Nakazato H; Ebihara E; Noma K; Kawano T; Nagamine K; Sakoda H; Nakazato M
    Diabetes Ther; 2018 Feb; 9(1):403-411. PubMed ID: 29322485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes.
    McKenzie AL; Hallberg SJ; Creighton BC; Volk BM; Link TM; Abner MK; Glon RM; McCarter JP; Volek JS; Phinney SD
    JMIR Diabetes; 2017 Mar; 2(1):e5. PubMed ID: 30291062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study.
    Kishimoto S; Higashi Y; Imai T; Eguchi K; Fukumoto K; Tomiyama H; Maemura K; Tanaka A; Node K;
    Cardiovasc Diabetol; 2023 May; 22(1):119. PubMed ID: 37210524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Effectiveness and Safety of Hydrogen Inhalation in Chinese Patients with Type 2 Diabetes: A Single-Arm, Retrospective Study.
    Ji H; Zhao Z; Liu Z; Sun R; Li Y; Ding X; Ni T
    Diabetes Metab Syndr Obes; 2023; 16():2039-2050. PubMed ID: 37431394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.